The use of Benincasa hispida for the treatment of uninvestigated dyspepsia: Preliminary results of a non-randomised open label pilot clinical trial

被引:2
|
作者
Vinaya, T. M. [1 ]
Aravind, B. S. [2 ]
Sibbritt, David [3 ]
Tapasbrata, Tripathy [4 ]
Shivakumar, S. [4 ]
机构
[1] JSS Ayurveda Med Coll, Dept Community Hlth & Prevent Med, Mysore 570028, Karnataka, India
[2] JSS Ayurveda Med Coll, Dept Physiol, Mysore, Karnataka, India
[3] Univ Technol Sydney, Fac Hlth, Ultimo, NSW 2007, Australia
[4] SDM Coll Ayurveda, Dept Community Hlth & Prevent Med, Hassan, Karnataka, India
关键词
Dyspepsia; Benincasa hispida; Ayurveda;
D O I
10.1016/j.aimed.2015.09.003
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Dyspepsia is becoming a common health problem for which an individual seeks medical help. The approach to the management of dyspepsia is complex with high treatment costs and possible adverse effects. Methods: A prospective pilot study was designed to assess the effectiveness of the fruit juice of Ash Gourd (Benincasa hispida) on twenty dyspeptic subjects, who were followed up for 45 days. Measures of retrosternal pain, post-prandial fullness, bloating, sour belching, nausea, vomiting and changes in bowel habits were taken at three times periods (baseline, 30 days and 45 days). Results: Statistically significant improvements were seen in several parameters, including pain (p<0.001), retrosternal burning (p<0.001), nausea (p<0.001),belching(p<0.001) and bowel habits (p<0.05),which are considered as the classical symptoms of dyspepsia. Bloating, though not a common symptom also improved (p<0.001) over time. Conclusion: The trial drug is an effective remedy for uninvestigated dyspepsia. Randomised controlled trials are further needed to confirm the pharmaco-dynamics of the trial drug for anti-ulcer, acid suppression, H-2 receptor antagonistic, anti-cholinergic properties. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:130 / 134
页数:5
相关论文
共 50 条
  • [31] Risperidone versus haloperidol treatment in dual diagnosis inpatients: preliminary results from a 6 week, randomized controlled, open label pilot trial
    Gimelfarb, Y.
    Natan, Z.
    Mashiah, M.
    Dlayahu, Y.
    EUROPEAN PSYCHIATRY, 2007, 22 : S194 - S194
  • [32] Investigating the clinical feasibility of an adapted early mobility readiness protocol for critical ill patients: A non-randomised experimental pilot trial
    Conradie, Elmarie
    Fourie, Catharina E.
    Hanekom, Susan D.
    INTENSIVE AND CRITICAL CARE NURSING, 2017, 42 : 44 - 50
  • [33] Esomeprazole treatment in patients with uninvestigated non-GERD dyspepsia leads to significant improvements in productivity while at work and in daily activities - Results from a randomised, placebo-controlled clinical study
    Wahlqvist, P
    Bergenheim, K
    Persson, T
    Brun, J
    Flook, N
    Lauritsen, K
    Vakil, N
    van Zanten, SV
    Zanten, S
    Talley, NJ
    VALUE IN HEALTH, 2005, 8 (06) : A125 - A125
  • [34] Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial
    Heyderman, Robert S.
    Madhi, Shabir A.
    French, Neil
    Cutland, Clare
    Ngwira, Bagrey
    Kayambo, Doris
    Mboizi, Robert
    Koen, Anthonet
    Jose, Lisa
    Olugbosi, Morounfolu
    Wittke, Frederik
    Slobod, Karen
    Dull, Peter M.
    LANCET INFECTIOUS DISEASES, 2016, 16 (05): : 546 - 555
  • [35] Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment
    Belcher, Annabelle M.
    Cole, Thomas O.
    Greenblatt, Aaron D.
    Hoag, Stephen W.
    Epstein, David H.
    Wagner, Michael
    Billing, Amy S.
    Massey, Ebonie
    Hamilton, Kristen R.
    Kozak, Zofia K.
    Welsh, Christopher J.
    Weintraub, Eric
    Wickwire, Emerson M.
    Wish, Eric D.
    Kaptchuk, Ted J.
    Colloca, Luana
    BMJ OPEN, 2019, 9 (06):
  • [36] Investigation of the effects of Chlorella vulgaris as an adjunctive therapy for dyslipidemia: Results of a randomised open-label clinical trial
    Panahi, Yunes
    Pishgoo, Bahram
    Jalalian, Hamid R.
    Mohammadi, Elaheh
    Taghipour, Hamid R.
    Sahebkar, Amirhossein
    Abolhasani, Ehsan
    NUTRITION & DIETETICS, 2012, 69 (01) : 13 - 19
  • [37] Nilotinib (Tasigna™) In The Treatment Of Early Diffuse Systemic Sclerosis: A Single Group, Open Label Pilot Clinical Trial - One Year Results
    Gordon, Jessica K.
    Magro, Cynthia
    Udeh, Uzunma
    Lerner, Daniele
    Wildman, Horatio F.
    Huang, Wei-Ti
    Crow, Mary K.
    Spiera, Robert F.
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S301 - S302
  • [38] Ano-coccygeal support in the treatment of idiopathic chronic posterior anal fissure: a prospective non-randomised controlled pilot trial
    T. Gee
    R. B. Hisham
    M. F. Jabar
    Y. A. Gul
    Techniques in Coloproctology, 2013, 17 : 181 - 186
  • [39] Ano-coccygeal support in the treatment of idiopathic chronic posterior anal fissure: a prospective non-randomised controlled pilot trial
    Gee, T.
    Hisham, R. B.
    Jabar, M. F.
    Gul, Y. A.
    TECHNIQUES IN COLOPROCTOLOGY, 2013, 17 (02) : 181 - 186
  • [40] Artemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Grande Comore island: an open-label, non-randomised controlled trial
    Li, Guoming
    Yuan, Yueming
    Zheng, Shaoqin
    Lu, Chenguang
    Li, Mingqiang
    Tan, Ruixiang
    Zhang, Hongying
    Silai, Rahamatou
    Liu, Ruimei
    Abdallah, Kamal Said
    Bacar, Affane
    Xu, Qin
    Song, Jianping
    Wu, Wanting
    Deng, Changsheng
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 60 (04)